In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $16.45 in the prior trading day, Summit Therapeutics Inc (NASDAQ: SMMT) closed at $16.19, down -1.58%. In other words, the price has decreased by -$1.58 from its previous closing price. On the day, 2.76 million shares were traded. SMMT stock price reached its highest trading level at $16.575 during the session, while it also had its lowest trading level at $15.62.
Ratios:
Our goal is to gain a better understanding of SMMT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On September 17, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $13.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $40.Guggenheim initiated its Buy rating on September 04, 2025, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 21 ’25 when Xia Yu bought 533,617 shares for $18.74 per share. The transaction valued at 9,999,983 led to the insider holds 32,057,147 shares of the business.
DUGGAN ROBERT W bought 26,680 shares of SMMT for $499,983 on Oct 21 ’25. The Co-Chief Executive Officer now owns 76,680 shares after completing the transaction at $18.74 per share. On Oct 21 ’25, another insider, Zanganeh Mahkam, who serves as the Co-Chief Executive Officer of the company, bought 26,680 shares for $18.74 each. As a result, the insider paid 499,983 and bolstered with 76,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 12052525056 and an Enterprise Value of 11819399168.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.39, which has changed by -0.15633142 over the last 52 weeks, in comparison to a change of 0.1028198 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $15.55. The 50-Day Moving Average of the stock is -17.12%, while the 200-Day Moving Average is calculated to be -26.80%.
Shares Statistics:
The stock has traded on average 3.95M shares per day over the past 3-months and 2278300 shares per day over the last 10 days, according to various share statistics. A total of 744.44M shares are outstanding, with a floating share count of 102.73M. Insiders hold about 86.17% of the company’s shares, while institutions hold 14.12% stake in the company. Shares short for SMMT as of 1761868800 were 32436319 with a Short Ratio of 8.22, compared to 1759190400 on 35934132. Therefore, it implies a Short% of Shares Outstanding of 32436319 and a Short% of Float of 27.389999999999997.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 11.0 analysts currently analyzing and rating the stock of Summit Therapeutics Inc (SMMT).The consensus estimate for the next quarter is -$0.04, with high estimates of $0.71 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.1 and -$1.12 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.74, with 10.0 analysts recommending between -$0.43 and -$1.18.
